Filing Flows › GeneDx Holdings (WGS) › Q1 2026 › vs Q1 2025
GeneDx Holdings (WGS) Q1 2026 vs Q1 2025 (year over year)
GeneDx Holdings's revenue rose $15.1M (+17%) from $87.1M in Q1 2025 to $102M in Q1 2026. The biggest changes: Diagnostic Test +$15.3M (+18%); Other revenue −$401K (-30%); Self-pay patients +$190K (+198%).
GeneDx Holdings, Q1 2026: revenue $102M (+17% year over year), operating margin -56.2%, net loss $63.3M, operating cash flow −$32.4M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Patients with third-party insurance | $84.9M | $68.1M | $16.9M | +25% |
| Institutional customers | $16.1M | $17.6M | −$1.5M | -9% |
| Diagnostic Test | $101M | $85.7M | $15.3M | +18% |
| Other revenue | $955K | $1.4M | −$401K | -30% |
| Self-pay patients | $286K | $96K | $190K | +198% |
| Revenue | $102M | $87.1M | $15.1M | +17% |
| Net loss | $63.3M | $6.5M | $56.8M | +870% |
| Costs & expenses | $166M | $93.6M | $71.9M | +77% |
| Operating costs | $160M | $91.7M | $68.1M | +74% |
| Interest & other, net | $4.9M | $1.5M | $3.4M | +223% |
| Income tax | $897K | $447K | $450K | +101% |
| Cost of revenue | $34.0M | $28.6M | $5.4M | +19% |
| Research & development | $19.8M | $12.6M | $7.2M | +57% |
| Operating cash sources | $63.3M | $6.5M | $56.8M | +870% |
| Depreciation & amortization | $6.8M | $5.7M | $1.1M | +20% |
| Share-based compensation | $9.0M | $4.0M | $5.0M | +126% |
| Working capital & other | $15.1M | $7.0M | $8.1M | +114% |
| Cash used in operations | $32.4M | −$10.2M | $42.6M | — |
| Net loss absorbed | $63.3M | $6.5M | $56.8M | +870% |
Questions
How much did GeneDx Holdings's revenue grow year over year in Q1 2026?
GeneDx Holdings's revenue rose $15.1M (+17%) from $87.1M in Q1 2025 to $102M in Q1 2026.
What drove GeneDx Holdings's revenue change in Q1 2026?
Diagnostic Test +$15.3M (+18%); Other revenue −$401K (-30%); Self-pay patients +$190K (+198%).